The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.
The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.
The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.
The round was led by Belgian billionaire and founder of Omega Pharma Marc Coucke.
Genycell will distribute the Sophia Data Driven Medicine platform as part of a package to laboratories and hospitals in Spain and Portugal.
The deals are expected to broaden the range of NGS tests in both countries and accelerate adoption of the technology.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.